Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 46Recruiting 13Terminated 12Unknown 9Active not recruiting 8Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Nasopharyngeal Carcinoma 11Squamous Cell Carcinoma of Head and Neck 9Small Cell Lung Carcinoma 9Uterine Cervical Neoplasms 7Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Esophageal Squamous Cell Carcinoma 5Cholangiocarcinoma 5Lung Neoplasms 4Head and Neck Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Neoplasms 3Endometrial Neoplasms 3Ovarian Neoplasms 2Neoplasms 2NSCLC 2Esophageal Neoplasms 2Breast Neoplasms 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Tongue Squamous Cell Carcinoma 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Solid Tumor Cancer 1Recurrence 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Paclitaxel 9Carboplatin 8Bevacizumab 8fluzoparib 5olaparib 3Topotecan 3Gemcitabine 3liposomal doxorubicin 2famitinib 2apatinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Drug Therapy 2Cisplatin 2trametinib 1senaparib 1pembrolizumab 1niraparib 1montelukast 1irinotecan sucrosofate 1fludarabine 1durvalumab 1dalpiciclib 1dabrafenib 1ceralasertib 1anlotinib 1aldesleukin 1Ultrasonography, Doppler 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Ovarian Neoplasms × Cisplatin × Clear all
NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Jiangsu Cancer Institute & Hospital

Phase 2 Not yet recruiting
50 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡